we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.
Company profile
Ticker
ALEC
Exchange
Website
CEO
Arnon Rosenthal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Alector LLC
SEC CIK
Corporate docs
Subsidiaries
Alector LLC ...
IRS number
462702363
ALEC stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
21 Mar 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Alector Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Alector Announces Pricing of Public Offering of Common Stock
19 Jan 24
424B5
Prospectus supplement for primary offering
19 Jan 24
8-K
Results of Operations and Financial Condition
16 Jan 24
424B5
Prospectus supplement for primary offering
16 Jan 24
8-K
Entry into a Material Definitive Agreement
7 Nov 23
424B5
Prospectus supplement for primary offering
7 Nov 23
Transcripts
Latest ownership filings
4
Mark Altmeyer
21 Mar 24
4
ERROL B DESOUZA
21 Mar 24
3
Mark Altmeyer
21 Mar 24
3
ERROL B DESOUZA
21 Mar 24
4
MARC GRASSO
5 Mar 24
4
Arnon Rosenthal
5 Mar 24
4
Gary Romano
5 Mar 24
4
Sara Kenkare-Mitra
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 103.51 mm | 103.51 mm | 103.51 mm | 103.51 mm | 103.51 mm | 103.51 mm |
Cash burn (monthly) | 9.86 mm | 6.85 mm | 16.86 mm | 13.31 mm | 15.51 mm | 15.58 mm |
Cash used (since last report) | 58.98 mm | 40.98 mm | 100.87 mm | 79.63 mm | 92.81 mm | 93.23 mm |
Cash remaining | 44.53 mm | 62.53 mm | 2.64 mm | 23.88 mm | 10.70 mm | 10.28 mm |
Runway (months of cash) | 4.5 | 9.1 | 0.2 | 1.8 | 0.7 | 0.7 |
Institutional ownership, Q3 2023
82.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 147 |
Opened positions | 21 |
Closed positions | 17 |
Increased positions | 57 |
Reduced positions | 39 |
13F shares | Current |
---|---|
Total value | 399.73 bn |
Total shares | 79.32 mm |
Total puts | 47.30 k |
Total calls | 55.70 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
FMR | 12.17 mm | $78.87 bn |
Polaris Venture Partners VI | 11.85 mm | $0.00 |
BLK Blackrock | 7.73 mm | $50.10 bn |
Vanguard | 5.52 mm | $35.78 bn |
Braidwell | 4.07 mm | $26.40 bn |
EcoR1 Capital | 4.06 mm | $26.29 bn |
MRK Merck & Co | 3.55 mm | $0.00 |
MS Morgan Stanley | 3.34 mm | $21.63 bn |
STT State Street | 2.84 mm | $18.38 bn |
JPM JPMorgan Chase & Co. | 2.29 mm | $14.83 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Mar 24 | Desouza Errol B | Common Stock | Grant | Acquire A | No | No | 0 | 41,250 | 0.00 | 41,250 |
19 Mar 24 | Desouza Errol B | Stock Option Common Stock | Grant | Acquire A | No | No | 6.2 | 19,420 | 120.40 k | 19,420 |
19 Mar 24 | Mark Altmeyer | Common Stock | Grant | Acquire A | No | No | 0 | 41,250 | 0.00 | 41,250 |
19 Mar 24 | Mark Altmeyer | Stock Option Common Stock | Grant | Acquire A | No | No | 6.2 | 19,420 | 120.40 k | 19,420 |
4 Mar 24 | Marc Grasso | Common Stock | Sell | Dispose S | No | No | 6.9212 | 5,716 | 39.56 k | 144,957 |
News
HC Wainwright & Co. Reiterates Buy on Alector, Maintains $41 Price Target
28 Feb 24
Recap: Alector Q4 Earnings
27 Feb 24
Alector Q4 2023 GAAP EPS $(0.49) Beats $(0.77) Estimate, Sales $15.19M Beat $9.64M Estimate
27 Feb 24
Earnings Scheduled For February 27, 2024
27 Feb 24
Earnings Outlook For Alector
26 Feb 24
Press releases
Alector to Participate in Upcoming Healthcare Conferences
28 Feb 24
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease
8 Feb 24
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
7 Feb 24
Alector Announces Closing of Public Offering
19 Jan 24
Alector Announces Pricing of Public Offering of Common Stock
17 Jan 24